An advanced MRI-based, single-centre investigation of high grade gliomas

Not Applicable

• Conditions: Glioblastoma, Isocitrate dehydrogenase (IDH)-wildtype; Grade 4 Astrocytoma, IDH-mutant; Cancer - Brain

• Registration Number: ACTRN12624001014549
• Lead Sponsor: niversity of Newcastle

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-08-21
• Last Update Posted: 26 August 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Untreated CNS WHO grade 4, adult-type diffuse glioma (GBM IDH-wildtype, or
Astrocytoma IDH-mutant),
• Adults aged 18 years or older,
• Participants capable of childbearing are using adequate contraception,
• Has provided written informed consent

Exclusion Criteria

• Patients who are pregnant, lactating / breastfeeding, or expecting pregnancy,
• Patients who are severely cognitively impaired, such that they are unable to provide
informed consent
• Reduced kidney function (determined by the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation for estimated Glomerular Filtration Rate (eGFR). An
eGFR < 30 mL/min/1.73m2 precludes administration of Gadovist (and therefore excludes them from participation),
• A prior resection of the primary lesion or radiotherapy treatment in the brain (i.e only newly diagnosed patients)
• Patients who are unable to lie flat for the duration of the MRI scan (of about an hour)

• Any contraindication to MRI scanning, including:
o Cardiac pacemaker or defibrillator,
o Metal fragments in the eye,
o Severe claustrophobia,
o Any other non-MRI compatible medical device/implant or medical condition.

Study & Design

• Study Type: Observational
• Study Design: Not specified